Somatostatinergic ligands in dopamine-sensitive and -resistant prolactinomas

European Journal of Endocrinology

Volumn 158, Issue 5, 2008, Pages 595-603

  Fusco, Alessandra ^a   Gunz, Ginette ^a   Jaquet, Philippe ^a   Dufour, Henry ^b   Germanetti, Anne Laure ^b   Guller, Michael D ^c   Barlier, Anne ^a,b   Saveanu, Alexandru ^a,b  

^a CNRS   (France)

^b ASSISTANCE PUBLIQUE HÔPITAUX DE MARSEILLE   (France)

^c IPSEN   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BETA GLUCURONIDASE; BIM 23197; BIM 23206; BIM 23926; BIM 23A760; CABERGOLINE; DOPAMINE 2 RECEPTOR; DOPAMINE RECEPTOR STIMULATING AGENT; HORMONE RECEPTOR STIMULATING AGENT; MESSENGER RNA; PASIREOTIDE; PROLACTIN; SOMATOSTATIN RECEPTOR; SOMATOSTATIN RECEPTOR 1; SOMATOSTATIN RECEPTOR 2; SOMATOSTATIN RECEPTOR 5; THYMIDINE;

ADULT; AGED; ARTICLE; BINDING AFFINITY; CLINICAL ARTICLE; CONTROLLED STUDY; DNA SYNTHESIS INHIBITION; DOSE RESPONSE; DRUG EFFICACY; DRUG RECEPTOR BINDING; FEMALE; GENE EXPRESSION; HORMONE INHIBITION; HORMONE RELEASE; HORMONE RESPONSE; HUMAN; HUMAN TISSUE; LIGAND BINDING; MALE; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; PROLACTINOMA; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION;

ADULT; ANTINEOPLASTIC AGENTS; DOPAMINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; ERGOLINES; FEMALE; GROWTH HORMONE-SECRETING PITUITARY ADENOMA; HUMANS; LIGANDS; MALE; MIDDLE AGED; PITUITARY NEOPLASMS; PROLACTINOMA; RECEPTORS, DOPAMINE D2; RECEPTORS, SOMATOSTATIN; RNA, MESSENGER; SOMATOSTATIN; TUMOR CELLS, CULTURED;

EID: 43149090261     PISSN: 08044643     EISSN: None     Source Type: Journal    
DOI: 10.1530/EJE-07-0806     Document Type: Article

References (37)

1. Casanueva FF, Molitch ME, Schlechte JA, Abs R, Bonert V, Bronstein MD, Brue T, Cappabianca P, Colao A, Fahlbusch R, Fideleff H, Hadani M, Kelly P, Kleinberg D, Laws E, Marek J, Scanlon M, Sobrinho LG, Wass JA & Giustina A. Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas. Clinical Endocrinology 2006 65 265-273.
2. Missale C, Nash SR, Robinson SW, Jaber M & Caron MG. Dopamine receptors: from structure to function. Physiological Reviews 1998 78 189-225.
3. Molitch ME. Pharmacologic resistance in prolactinoma patients. Pituitary 2005 8 43-52.
4. Gillam MP, Molitch ME, Lombardi G & Colao, A. Advances in the treatment of prolactinomas. Endocrine Reviews 2006 27 485-534.
5. Jaquet P, Ouafik L, Saveanu A, Gunz G, Fina F, Dufour H, Culler MD, Moreau JP & Enjalbert A. Quantitative and functional expression of somatostatin receptor subtypes in human prolactinomas. Journal of Clinical Endocrinology and Metabolism 1999 84 3268-3276.
6. Shimon I, Yan X, Taylor JE, Weiss MH, Culler MD & Melmed S. Somatostatin receptor (SSTR) subtype-selective analogues differentially suppress in vitro growth hormone and prolactin in human pituitary adenomas. Novel potential therapy for functional pituitary tumors. Journal of Clinical Investigation 1997 100 2386-2392.
7. Jaquet P, Gunz G, Saveanu A, Dufour H, Taylor J, Dong J, Kim S, Moreau JP, Enjalbert A & Culler MD. Efficacy of chimeric molecules directed towards multiple somatostatin and dopamine receptors on inhibition of GH and prolactin secretion from GH-secreting pituitary adenomas classified as partially responsive to somatostatin analog therapy. European Journal of Endocrinology 2005 153 135-141.
8. Bruns C, Lewis I, Briner U, Meno-Tetang G & Weckbecker G. SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile. European Journal of Endocrinology 2002 146 707-716.
9. Jaquet P, Gunz G, Saveanu A, Barlier A, Dufour H, Taylor J, Dong J, Kim S, Moreau JP & Culler MD. BIM-23A760, a chimeric molecule directed towards somatostatin and dopamine receptors, vs universal somatostatin receptors ligands in GH-secreting pituitary adenomas partial responders to octreotide. Journal of Endocrinological Investigation 2005 28 21-27.
10. Saveanu A, Lavaque E, Gunz G, Barlier A, Kim S, Taylor JE, Culler MD, Enjalbert A & Jaquet P. Demonstration of enhanced potency of a chimeric somatostatin-dopamine molecule, BIM-23A387, in suppressing growth hormone and prolactin secretion from human pituitary somatotroph adenoma cells. Journal of Clinical Endocrinology and Metabolism 2002 87 5545-5552.
11. Jaquet P, Gunz G & Grisoli F. Hormonal regulation of prolactin release by human prolactinoma cells cultured in serum-free conditions. Hormone Research 1985 22 153-163.
12. Florio T, Thellung S, Arena S, Corsaro A, Spaziante R, Gussoni G, Acuto G, Giusti M, Giordano G & Schettini G. Somatostatin and its analog lanreotide inhibit the proliferation of dispersed human non-functioning pituitary adenoma cells in vitro. European Journal of Endocrinology 1999 141 396-408.
13. Pellegrini I, Rasolonjanahary R, Gunz G, Bertrand P, Delivet S, Jedynak CP, Kordon C, Peillon F, Jaquet P & Enjalbert A. Resistance to bromocriptine in prolactinomas. Journal of Clinical Endocrinology and Metabolism 1989 69 500-509.
14. Nielsen S, Mellemkjaer S, Rasmussen LM, Ledet T, Astrup J, Weeke J & Jorgensen JO. Gene transcription of receptors for growth hormone-releasing peptide and somatostatin in human pituitary adenomas. Journal of Clinical Endocrinology and Metabolism 1998 83 2997-3000.
15. Miller GM, Alexander JM, Bikkal HA, Katznelson L, Zervas NT & Klibanski A. Somatostatin receptor subtype gene expression in pituitary adenomas. Journal of Clinical Endocrinology and Metabolism 1995 80 1386-1392.
16. Murabe H, Shimatsu A, Ihara C, Mizuta H, Nakamura Y, Nagata I, Kikuchi H & Nakao K. Expression of somatostatin receptor (SSTR) subtypes in pituitary adenomas: quantitative analysis of SSTR2 mRNA by reverse transcription-polymerase chain reaction. Journal of Neuroendocrinology 1996 8 605-610.
17. Holland LJ, De Herder WW, Visser-Wisselaar HA, Van Uffelen C, Waaijers M, Zuyderwijk J, Uitterlinden P, Kros MJ, Van Koetsveld PM & Lamberts SW. Dissociation between the effects of somatostatin (SS) and octapeptide SS-analogs on hormone release in a small subgroup of pituitary- and islet cell tumors. Journal of Clinical Endocrinology and Metabolism 1997 82 3011-3018.
18. Panetta R & Patel YC. Expression of mRNA for all five human somatostatin receptors (hSSTR1-5) in pituitary tumors. Life Sciences 1995 56 333-342.
19. Greenman Y & Melmed S. Expression of three somatostatin receptor subtypes in pituitary adenomas: evidence for preferential SSTR5 expression in the mammosomatotroph lineage. Journal of Clinical Endocrinology and Metabolism 1994 79 724-729.
20. Thodou E, Kontogeorgos G, Theodossiou D & Pateraki M. Mapping of somatostatin receptor types in GH or/and PRL producing pituitary adenomas. Journal of Clinical Pathology 2006 59 274-279.
21. Patel RC, Kumar U, Lamb DC, Eid JS, Rocheville M, Grant M, Rani A, Hazlett T, Patel SC, Gratton E & Patel YC. Ligand binding to somatostatin receptors induces receptor-specific oligomer formation in live cells. PNAS 2002 99 3294-3299.
22. Hakovic N, Rocheville M, Kumar U, Sasi R, Khare S & Patel YC. Agonist-dependent up-regulation of human somatostatin receptor type 1 requires molecular signals in the cytoplasmic C-tail. Journal of Biological Chemistry 1999 274 24550-24558.
23. Nouel D, Gaudriault G, Houle M, Reisine T, Vincent JP, Mazella J & Beaudet A. Differential internalization of somatostatin in COS-7 cells transfected with SST1 and SST2 receptor subtypes: a confocal microscopic study using novel fluorescent somatostatin derivatives. Endocrinology 1997 138 296-306.
24. Rocheville M, Lange DC, Kumar U, Sasi R, Patel RC & Patel YC. Subtypes of the somatostatin receptor assemble as functional homo- and heterodimers. Journal of Biological Chemistry 2000 275 7862-7869.
25. Chen L, Fitzpatrick VD, Vandlen RL & Tashjian AH, Jr. Both overlapping and distinct signaling pathways for somatostatin receptor subtypes SSTR1 and SSTR2 in pituitary cells. Journal of Biological Chemistry 1997 272 18666-18672.
26. Buscail L, Delesque N, Esteve JP, Saint-Laurent N, Prats H, Clerc P, Robberecht P, Bell GI, Liebow C, Schally AV, Vaysse N & Susini C. Stimulation of tyrosine phosphatase and inhibition of cell proliferation by somatostatin analogues: mediation by human somatostatin receptor subtypes SSTR1 and SSTR2. PNAS 1994 91 2315-2319.
27. Arena S, Pattarozzi A, Massa A, Esteve JP, Iuliano R, Fusco A, Susirri C & Florio T. An intracellular multi-effector complex mediates somatostatin receptor 1 activation of phospho-tyrosine phosphatase eta. Molecular Endocrinology 2007 21 229-246.
28. Florio T, Thellung S, Arena S, Corsarc, A, Bajetto A, Schettini G & Stork PJ. Somatostatin receptor 1 (SSTR1)-mediated inhibition of cell proliferation correlates with the activation of the MAP kinase cascade: role of the phosphotyrosine phosphatase SHP-2. Journal of Physiology 2000 94 239-250.
29. Cattaneo MG, Taylor JE, Culler MD, Nisoli E & Vicentini LM. Selective stimulation of somatostatin receptor subtypes: differential effects on Ras/MAP kiriase pathway and cell proliferation in human neuroblastoma cells. FEBS Letters 2000 481 271-276.
30. Zatelli MC, Piccin D, Tagliati F, Ambrosio MR, Margutti A, Padovani R, Scanarini M, Culler MD & Degli Uberti EC. Somatostatin receptor subtype 1 selective activation in human growth hormone (GH)- and prolactin (PRL)-secreting pituitary adenomas: effects on cell viability, GH and PRL secretion. Journal of Clinical Endocrinology and Metabolism 2003 88 2797-2802.
31. Zatelli MC, Piccin D, Bottoni A, Ambrosio MR, Margutti A, Padovani R, Scanarini M, Taylor JE, Culler MD, Cavazzin! L & Degli Uberti EC. Evidence for differential effects of selective somatostatin receptor subtype agonists on alpha-subunit and chromogranin a secretion and on cell viability in human nonfunctioning pituitary adenomas in vitro. Journal of Clinical Endocrinology and Metabolism 2004 89 5181-5188.
32. Zatelli MC, Piccin D, Tagliati F, Bottoni A, Luchin A, Vignali C, Margutti A, Bondanelli M, Pansini GC, Pelizzo MR, Culler MD & Degli Uberti EC. Selective activation of somatostatin receptor subtypes differentially modulates secretion and viability in human medullary thyroid carcinoma primary cultures: potential clinical perspectives. Journal of Clinical Endocrinology and Metabolism 2006 91 2218-2224.
33. Matrone C, Pivonello R, Colao A, Cappabianca P, Cavallo LM, Del Basso De Caro ML, Taylor JE, Culler MD, Lombardi G, Di Renzo GF & Annuriziato L. Expression and function of somatostatin receptor subtype 1 in human growth hormone secreting pituitary tumors deriving from patients partially responsive or resistant to long-term treatment with somatostatin analogs. Neuroendocrinology 2004 79 142-148.
34. Grant M, Patel RC & Kumar U. The role of subtype-specific ligand binding and the C-tail domain in dimer formation of human somatostatin receptors. Journal of Biological Chemistry 2004 279 38636-38643.
35. Holland LJ, Van Der Hoek J, Van Koetsveld PM, De Herder WW, Waaijers M, Sprij-Mooij D, Bruns C, Weckbecker G, Feelders R, Van Der Lely AJ, Beckers A & Lamberts SW The novel somatostatin analog SOM230 is a potent inhibitor of hormone release by growth hormone-and prolactin-secreting pituitary adenomas in vitro. Journal of Clinical Endocrinology and Metabolism 2004 89 1577-1585.
36. Rocheville M, Lange DC, Kumar U, Patel SC, Patel RC & Patel YC. Receptors for dopamine and somatostatin: formation of hetero-oligomers with enhanced functional activity. Science 2000 288 154-157.
37. Gruszka A, Ren SG, Dong J, Culler MD & Melmed S. Regulation of growth hormone and prolactin gene expression and secretion by chimeric somatostatin-dopamine molecules. Endocrinology 2007 148 6107-6114.